Shopping Cart
Remove All
Your shopping cart is currently empty
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $74 | In Stock | In Stock | |
| 5 mg | $179 | In Stock | In Stock | |
| 10 mg | $272 | In Stock | In Stock | |
| 25 mg | $463 | In Stock | In Stock | |
| 50 mg | $662 | In Stock | In Stock | |
| 100 mg | $928 | In Stock | In Stock |
| Description | Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR. |
| Targets&IC50 | EGFR (WT):0.611 nM, HER4:84 nM, EGFR (T790M):45.2 nM, BLK:102 nM, IRAK1:167 nM, EGFR (L861Q):0.423 nM, BTK:196 nM, HER2:253 nM, EGFR (L858R):0.563 nM |
| In vivo | Larotinib (250, 300, 350 mg; oral; once daily; patients) demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.[1] |
| Molecular Weight | 488.94 |
| Formula | C24H26ClFN4O4 |
| Cas No. | 1438072-11-7 |
| Smiles | N(C=1C2=C(C=C(OC)C(OCCCN3C[C@@]4([C@](C3)(OCCO4)[H])[H])=C2)N=CN1)C5=CC(Cl)=C(F)C=C5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (122.71 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.